Transcriptomics Sequencing and analysis in Liver Spheroids
ID: 75N95025Q00040Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIDABethesda, MD, 20892, USA

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

PSC

MEDICAL- LABORATORY TESTING (Q301)
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Center for Advancing Translational Sciences (NCATS), is seeking a contractor to provide transcriptomics sequencing and analysis in liver spheroids to evaluate the hepatotoxicity of antisense oligonucleotides (ASOs). The primary objective of this contract is to develop a predictive model for assessing the safety and acute toxicity of ASO therapies, particularly for rare diseases, by utilizing 3D liver microtissue platforms to replace traditional animal studies. This initiative is crucial for enhancing the safety profiles of potential ASO therapies intended for clinical use, addressing significant public health concerns. Interested parties can contact Chandani Hangilipola at chandani.hangilipola@nih.gov or call 13014807089 for further details, with the project expected to commence on October 20, 2024, and conclude by December 20, 2024.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Center for Advancing Translational Sciences (NCATS) is seeking a contract to evaluate RNA expression related to liver toxicity from antisense oligonucleotides (ASOs) in animal models. The goal is to develop a predictive model for assessing the safety and acute toxicity of ASO therapies, especially for rare diseases, where current drug development processes are costly and slow. The focus is on validating whether 3D liver microtissue platforms can reliably predict ASO hepatotoxicity, potentially replacing conventional animal studies with more efficient screening methods. The contract entails testing eight known hepatotoxic ASOs against safe counterparts using a 3D liver assay and RNA sequencing to assess gene expression over specific time points. The project aims to generate proof-of-concept data to facilitate regulatory approval processes and decrease development timelines for therapies targeting rare diseases. The performance period for this study is scheduled from October 20, 2024, to December 20, 2024, with a comprehensive report due at the end of the study.
    The document outlines the requirements for federal contractors regarding “covered telecommunications equipment or services” under provision 52.204-26. It defines key terms and establishes the necessary procedures for offerors participating in government contracts. Offerors must verify whether they provide any covered telecommunications products or services in accordance with guidelines that prevent contracting with entities involved in certain telecommunications sectors. Specifically, they are required to conduct a reasonable inquiry, referencing the System for Award Management (SAM) for excluded parties, and must formally represent their compliance status regarding the use of such telecommunications equipment. The provision concludes with a certification section to be completed by an authorized individual from the organization, confirming their findings. Overall, the document emphasizes the importance of due diligence in maintaining government standards for telecommunications used in federal projects.
    The document serves as an addendum to FAR 52.212-4, outlining the order of precedence for resolving inconsistencies in government contracts for commercial products and services. It establishes a hierarchy that starts with the schedule of supplies/services and progresses through various clauses and attachments. Key components address commercial supplier agreements (CSAs), defining them as standard terms provided by vendors that bind end users, particularly applicable in IT acquisitions. Provisions included stipulate that agreements bind the government as an end user, ensuring that only federal law governs these contracts while excluding state laws and specifying dispute resolution procedures. Significant items cover the unilaterally revisable terms post-award, limitations on automatic renewals, privileges regarding audits, and requirements concerning taxes or surcharges passed to the government. It also mentions confidentiality obligations and outlines that any provisions contradicting the contract’s terms are unenforceable. This addendum emphasizes the importance of clarity and adherence to federal regulations in commercial contracts, ensuring that the U.S. Government’s legal obligations and rights are protected effectively in relation to commercial transactions.
    The provision 52.204-24 outlines regulations regarding telecommunications and video surveillance services in government contracts. It is part of a requirement to ensure that Offerors do not provide or utilize covered telecommunications equipment or services outlined in the John S. McCain National Defense Authorization Act of 2019. The provision includes representations that Offerors must complete, indicating whether they will supply such equipment or services to the government. Definitions and prohibitions are specified, alongside the requirement for Offerors to review the System for Award Management (SAM) for excluded parties. Additional disclosures are mandated for those who represent they will provide or do use covered telecommunications equipment or services, including details about the equipment or services offered and their proposed use. The primary purpose is to safeguard national security by prohibiting the use of certain technologies deemed critical and potentially harmful. Overall, this provision reflects the government's effort to mitigate risks associated with telecommunications services utilized in federal contracting.
    The National Institute on Drug Abuse (NIDA) is soliciting a non-competitive request for quotation (RFQ) for Transcriptomics Sequencing and Analysis in Liver Spheroids, aimed at evaluating the hepatotoxicity of antisense oligonucleotides (ASOs). This contract will be awarded solely to Insphero Inc., as part of the National Center for Advancing Translational Sciences' (NCATS) efforts to address the challenges of rare diseases, where effective therapies are often absent. The project is designed to utilize the 3D Insight liver microtissues developed by Insphero to assess the safety of various ASOs, including both hepatotoxic and non-hepatotoxic variants. Deliverables include a comprehensive report of the gene expression results from the RNA sequencing for multiple test groups and conditions. The work is expected to be conducted by qualified scientists, with a project timeline of 8 weeks post-award. Proposals must include technical capabilities and pricing while adhering to established federal regulations. The initiative underscores the government's commitment to enhancing safety profiles for potential ASO therapies in clinical use, addressing a significant public health concern for millions affected by rare diseases.
    The document pertains to the Federal Acquisition Regulation (FAR) clause 52.212-5, which outlines the contract terms and conditions required to implement statutes or executive orders related to the acquisition of commercial products and services. It details specific FAR clauses that contractors must comply with, highlighting aspects such as contractor ethics, whistleblower protections, service contract reporting requirements, and restrictions on subcontractor sales. It also addresses various requirements for small business concerns, including set-asides and subcontracting plans, as well as compliance mandates regarding labor standards and environmental protections. The purpose of the document is to ensure that contractors are aware of and fulfill legal obligations as required by federal statutes and executive orders governing acquisitions. Compliance with these terms is essential in maintaining integrity, promoting equal opportunity, and safeguarding public funds. The structured listing of clauses provides a comprehensive guide for contractors engaged in federal contracting, emphasizing the significance of adherence to these regulations to achieve ethical and lawful contracting practices.
    The document outlines invoice and payment provisions relevant to contractors associated with the federal government, specifically focusing on the implementation of the Prompt Payment Act. Key requirements for proper invoicing include detailed information such as contractor identification, remit-to addresses, unique identifiers, and descriptions that align with contract specifications. The submission of invoices must be done electronically via the Department of Treasury’s Invoice Processing Platform (IPP). Payment timelines stipulate that invoices should be paid within 30 days of receipt or government acceptance. Additionally, it highlights conditions under which interest penalties may be applied for late payments, stressing the need for adherence to invoicing guidelines to avoid payment disputes. Furthermore, it mandates accelerated payment to small business subcontractors upon receipt of correct invoices, reinforcing the need for timely reimbursements. Overall, this document serves to ensure compliance with federal invoicing regulations and to facilitate efficient financial transactions within government contracts and grants. The structured format assists in providing clear guidance to contractors on the necessary procedures and requirements for payment requests.
    The document provides detailed guidance on invoice and payment provisions for Contractors and Vendors working with the National Institutes of Health (NIH), emphasizing compliance with the Prompt Payment Act and the transition to electronic invoicing through the Treasury’s Invoice Processing Platform (IPP). Key requirements for submission of invoices include mandatory invoice elements such as the vendor's details, unique entity identifier, and contract/purchase order numbers. Invoices must be submitted via email in specific formats, with a proper subject line for processing. Payment terms dictate that invoices are due within 30 days of receipt or government acceptance of services, with interest penalties applicable for late payments under certain conditions. Furthermore, the document outlines the need for accelerated payments to small business subcontractors, encouraging timely remuneration while adhering to regulations. Instructions for contacting customer service about invoice inquiries and mandatory electronic formats for submission ensure streamlined communication and efficiency in the payment process. Overall, this guidance is integral for maintaining compliance and facilitating timely transactions in federally funded projects.
    Lifecycle
    Title
    Type
    Combined Synopsis/Solicitation
    Similar Opportunities
    Repair of Novaseq6000 next generation sequencing instrument
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Center for Advancing Translational Sciences (NCATS), is seeking a contractor for the repair of a Novaseq6000 next-generation sequencing instrument. The primary objective of this procurement is to replace the Line Generation Module (LGM), a critical component necessary for the instrument's effective operation in RNA sequencing, which is vital for ongoing stem cell research. The Novaseq6000 plays a significant role in analyzing gene expression profiles, thereby contributing to advancements in diagnostics and therapeutics for various human diseases. Interested contractors should direct their proposals, which must include evidence of technical capability and detailed pricing, to the Contract Specialist, Chandani Hangilipola, at chandani.hangilipola@nih.gov, with a performance period expected to be completed within seven days post-order receipt.
    Support for Evaluating and Conducting Computational and Alternative Toxicological Methods for the National Institute of Environmental Health Sciences
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institute of Health's National Institute of Environmental Health Sciences (NIEHS), is seeking small businesses to provide support for evaluating and conducting computational and alternative toxicological methods. The primary objective of this procurement is to enhance human health hazard assessments while minimizing the use of animal testing, focusing on innovative methodologies such as computational toxicology and in vitro approaches. This initiative is crucial for advancing toxicological science and improving testing practices, reflecting the federal government's commitment to public health and environmental safety. Interested parties must submit their responses by November 29, 2024, and can direct inquiries to Megan Bang at megan.bang@nih.gov or Erica Kitzmiller at erica.kitzmiller@nih.gov.
    A--National Gene Vector Biorepository (NGVB)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is preparing to issue a Request for Proposals (RFP) for the National Gene Vector Biorepository (NGVB) program, aimed at supporting translational gene therapy research over a five-year period. The selected contractor will be tasked with archiving over 20,000 clinical specimens under Good Laboratory Practices (GLP), developing assays for clinical testing, and maintaining a user-friendly web-based catalogue for gene therapy reagents, all while ensuring compliance with FDA regulations. This initiative underscores the government's commitment to advancing gene therapy research and enhancing the services provided by the NGVB. Interested parties should note that the RFP details are expected to be released on November 22, 2024, and can contact Ethan J. Mueller at ethan.mueller@nih.gov or +1 301 496 2153 for further information.
    Sequencing Kits and Accessories for Oxford Nanopore Sequencing Systems
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources to provide sequencing kits and accessories for Oxford Nanopore Sequencing Systems as part of a Sources Sought notice. The primary objective of this procurement is to supply the Center for Alzheimer’s Disease and Related Dementias with essential reagents for neurodegenerative disease research, particularly for long read sequencing aimed at identifying causative genes for conditions like Parkinson’s disease. This initiative is aligned with the Global Parkinson’s Genetics Program (GP2), which aims to genotype over 150,000 volunteers globally to enhance understanding of genetic risk factors. Interested companies must submit their capability statements by November 27, 2024, to Eric McKay at eric.mckay@nih.gov, with the anticipated delivery dates for the supplies spanning from September 30, 2025, to September 30, 2027.
    Support for Evaluating and Conducting Computational and Alternative Toxicological Methods for the National Institute of Environmental Health Sciences
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institute of Environmental Health Sciences (NIEHS), is seeking support for evaluating and conducting computational and alternative toxicological methods through solicitation number 75N96025R00004. The procurement aims to assist NIEHS in conducting toxicological testing using New Approach Methodologies (NAMs) that do not rely on animal testing, focusing on areas such as population variability, susceptibility, and various toxicity assessments. This initiative is crucial for advancing alternative toxicity testing methods that align with the mission of the Department of Health & Human Services to predict adverse human health effects from chemical exposures. Interested parties should note that the solicitation is expected to be issued within 15 days, with proposals due approximately 30 days after release, and can contact Megan Bang at megan.bang@nih.gov for further inquiries.
    RNasin Plus RNase Inhibitor or Equivalent
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking information from qualified sources regarding the availability of RNasin Plus RNase Inhibitor or equivalent products for neurodegenerative disease research. The primary objective is to procure reagents that will assist in sequencing small RNA transcripts from Alzheimer’s Disease patient samples, which is crucial for identifying potential therapeutic targets and biomarkers. This procurement is vital for advancing the understanding of gene expression differences in Alzheimer’s Disease, thereby contributing to the overall research efforts in this area. Interested companies must submit their capability statements to Eric McKay at eric.mckay@nih.gov by November 27, 2024, at 4:00 p.m. Eastern Time, with no costs incurred by the government for responses.
    NCATS Scientific and Technology Program Support
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources to provide scientific and technological program support for the National Center for Advancing Translational Sciences (NCATS). The procurement aims to enhance NCATS's integrated research environment through comprehensive support across various task areas, including laboratory automation, data science, cybersecurity, and training, to facilitate innovative research and accelerate scientific breakthroughs. This initiative is crucial for maintaining the tools, infrastructure, and expertise necessary for NCATS researchers to conduct cutting-edge research effectively. Interested parties must submit their capability statements by email to Nick Niefeld at nick.niefeld@nih.gov by November 29, 2024, at 11:00 a.m. Eastern time, as this is a Sources Sought notice and not a solicitation for proposals.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services to support the development of drug products. The primary objective of this procurement is to ensure the provision of high-quality formulated drug products necessary for preclinical and clinical studies, adhering to current Good Manufacturing Practice (cGMP) regulations. This contract is crucial for advancing human therapeutics by facilitating the movement of drug candidates through the preclinical development process until the submission of Investigational New Drug (IND) applications. The Request for Proposals (RFP) is expected to be released on or about December 2, 2024, with contract awards anticipated in the third quarter of FY2025. Interested parties can contact Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    Pathology Monitoring of Aged Rodent Colonies
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Aging (NIA), is seeking proposals for a federal contract titled "Pathology Monitoring of Aged Rodent Colonies." This contract aims to perform clinical evaluations of aged mice and rats from NIA colonies, including health assessments and reporting results to the NIA Contracting Officer Representative (COR). The selected contractor will evaluate between 600 and 1,200 animals annually, conducting various tests and examinations to monitor their health, with a contract period anticipated to begin around March 1, 2025, and lasting for five years. Interested parties should note that the solicitation is expected to be released on November 19, 2024, and may contact Eric McKay at eric.mckay@nih.gov or 301-480-2406 for further information.
    A--To award Indefinite Delivery Indefinite Quantity (IDIQ) Contract for a Biologic
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to fulfill an Indefinite Delivery Indefinite Quantity (IDIQ) contract for the Biological Testing Facility (BTF), which focuses on the preclinical development of contraceptive products. The objective of this procurement is to support the discovery and optimization of anti-fertility agents, ensuring safety and efficacy evaluations that meet regulatory standards for clinical trials, ultimately aiding in the development of high-quality reproductive health products. Interested small businesses must demonstrate their qualifications, including compliance with Good Laboratory Practice and Good Manufacturing Practice, and provide capability statements by November 21, 2024, with the anticipated contract performance period running from September 3, 2025, to September 2, 2032. For further inquiries, interested parties may contact Adelola O. St John at lk202p@nih.gov or call 301-435-6955.